A new study published in the journal Progress in Neuro-Psychopharmacology & Biological Psychiatry has found that our body’s endocannabinoid system may provide a novel target for treatment of schizophrenia symptoms.
“Accumulating evidence suggests involvement of the endocannabinoid system in the pathophysiology of schizophrenia, which signifies a potential application for this system in the treatment of this disorder”, claims the study’s abstract. “Here we review human studies that investigated acute effects of cannabis or ∆9-tetrahydrocannabinol (THC) on brain functions that are implicated in schizophrenia.”
Their examination, according to researchers, provides “an argument for a role of the endocannabinoid system in symptoms of schizophrenia, and further emphasise this system as a potential novel target for treatment of these symptoms.”
The study was conducted by researchers at King’s College London, and the University Medical Center Utrecht.